Present Role of Corticosteroids as Antiemetics (Q37199907)

18 August 2017

1 reference

title

Present role of corticosteroids as antiemetics (English)

1 reference

18 August 2017

Present Role of Corticosteroids as Antiemetics (English)

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

11 December 2022

author name string

M. S. Aapro

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1857888

11 December 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1857888

11 December 2022

publication date

1 January 1991

1 reference

full work available at URL

18 August 2017

http://link.springer.com/content/pdf/10.1007/978-3-642-84138-5_11.pdf

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

Recent Results in Cancer Research

11 December 2022

published in

1 reference

18 August 2017

volume

121

1 reference

18 August 2017

page(s)

91-100

1 reference

A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer

18 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

Double-blind crossover study of the antiemetic efficacy of high-dose dexamethasone versus high-dose metoclopramide

11 December 2022

2

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

Neuropharmacology of Chemotherapy-induced Emesis

11 December 2022

3

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

The gastrointestinal tract in chemotherapy-induced emesis. A final common pathway

11 December 2022

4

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

Advances in anti-emetic therapy

11 December 2022

6

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

Schweizerische medizinische Wochenschrift

11 December 2022

7

111

1614

R Joss

1981

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

Methodologic issues in trials of antiemetics.

11 December 2022

8

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

11 December 2022

9

70

555

IN Olver

1986

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

Journal of the National Cancer Institute

11 December 2022

10

68

585

GR Morrow

1982

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

Is cancer treatment toxicity accurately reported?

11 December 2022

11

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

Early diagnosis of relapse in acute myeloblastic leukemia: Serologic detection of leukemia-associated antigens in human marrow

11 December 2022

13

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

Methylprednisolone as an antiemetic during cancer chemotherapy--a pilot study

11 December 2022

14

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

The New England Journal of Medicine

11 December 2022

15

486

304

BJ Lee

1981

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

High-dose dexamethasone for prevention of cis-platin-induced vomiting

11 December 2022

16

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

Behavioral Treatment for the Anticipatory Nausea and Vomiting Induced by Cancer Chemotherapy

11 December 2022

17

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

11 December 2022

18

12

2058

JL Breau

1983

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

Methylprednisolone as an Antiemetic in Patients on Cis-Platinum Chemotherapy. Results of a Controlled Randomized Study

11 December 2022

20

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

Randomized open cross-over trial between Metoclopramide (MCP) and dexamethazone (DXM) for the prevention of cisplatin-induced nausea and vomiting

11 December 2022

21

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

Comparison of methylprednisolone and metoclopramide in the prophylactic treatment of cis-platin-induced nausea and vomiting

11 December 2022

22

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

Antiemetic efficacy of dexamethasone. Randomized, double-blind, crossover study with prochlorperazine in patients receiving cancer chemotherapy

11 December 2022

23

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

Dexamethasone vs. placebo for cisplatin-induced emesis. A randomized cross-over trial

11 December 2022

24

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

Antiemetic efficacy of high-dose dexamethasone versus placebo in patients receiving cisplatin-based chemotherapy: a randomized double-blind controlled clinical trial.

11 December 2022

25

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

Randomized crossover antiemetic study in cisplatin-treated patients. Comparison between high-dose i.v. metoclopramide and high-dose i.v. dexamethasone

11 December 2022

26

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

European Journal of Cancer & Clinical Oncology

11 December 2022

27

39

619

EM Ibrahim

1986

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

Japanese Journal of Cancer and Chemotherapy

11 December 2022

29

13

2376

T Niijima

1986

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

11 December 2022

30

3

333

S Chiara

1984

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

The antiemetic efficacy of methylprednisolone compared with metoclopramide in outpatients receiving adjuvant CMF chemotherapy for breast cancer: a randomized trial

11 December 2022

31

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

Comparison of methylprednisolone and metoclopramide in the prophylactic treatment of cis-platin-induced nausea and vomiting

11 December 2022

32

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

Methylprednisolone in cis-platinum induced nausea and emesis: a placebo-controlled trial

11 December 2022

34

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

Comparison of antiemetic efficacy of domperidone, metoclopramide, and dexamethasone in patients receiving outpatient chemotherapy regimens

11 December 2022

36

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

Double-blind controlled trial of the antiemetic efficacy and toxicity of methylprednisolone (MP), metoclopramide (MTC) and domperidone (DMP) in breast cancer patients treated with i.v. CMF.

11 December 2022

37

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

Antiemetic efficacy of high-dose dexamethasone: randomized, double-blind, crossover study with a combination of dexamethasone, metoclopramide and diphenhydramine

11 December 2022

38

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

A double-blind trial comparing antiemetic efficacy and toxicity of metoclopramide versus methylprednisolone versus domperidone in patients receiving doxorubicin chemotherapy alone or in combination with other antiblastic agents.

11 December 2022

39

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

Methylprednisolone versus Metoclopramide for Prevention of Nausea and Vomiting in Breast Cancer Patients Treated with Intravenous Cyclophosphamide Methotrexate 5-Fluorouracil: A Double-Blind Randomized Study

11 December 2022

40

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

Double-blind randomized cross-over trial of dexamethasone and prochlorperazine as anti-emetics for cancer chemotherapy

11 December 2022

41

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

Effective Control of CMF-Related Emesis with High-Dose Dexamethasone

11 December 2022

42

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

High-dose intravenous metoclopramide versus combination high-dose metoclopramide and intravenous dexamethasone in preventing cisplatin-induced nausea and emesis: a single-blind crossover comparison of antiemetic efficacy

11 December 2022

43

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

11 December 2022

46

67

381

E Bruera

1986

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

Adrenocorticotropic hormone in the prevention of cisplatin-induced nausea and vomiting

11 December 2022

47

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

Dexamethasone and high dose metoclopramide: efficacy in controlling cisplatin induced nausea and vomiting.

11 December 2022

48

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

Antiemetic efficacy of high-dose corticosteroids and droperidol in cisplatin-induced emesis: a controlled trial with droperidol and metoclopramide

11 December 2022

49

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

11 December 2022

50

68

1310

N Panza

1984

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

The use of methylprednisolone and metoclopramide in control of emesis in patients receiving cis-platinum

11 December 2022

51

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

Antiemetic efficacy of moderately high-dose metoclopramide in patients receiving varying doses of cisplatin. Controlled comparison with a combination of methylprednisolone and metoclopramide

11 December 2022

52

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

Improved control of cisplatin-induced emesis with a combination of high doses of methylprednisolone and metoclopramide: a single-blind randomized trial

11 December 2022

53

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

Japanese Journal of Cancer and Chemotherapy

11 December 2022

54

13

2562

M Fujii

1986

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

Progress in Clinical and Biological Research

11 December 2022

55

216

407

SN Rhinehart

1986

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

[Prevention of nausea and emesis during cytostatic therapy. Antiemetic efficacy of high-dosage oral metoclopramide without and with prednisone]

11 December 2022

56

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

Comparison of metoclopramide and metoclopramide plus dexamethasone for complete protection from cisplatinum-induced emesis

11 December 2022

58

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

Antiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research.

11 December 2022

59

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

High doses of methylprednisolone with or without alizapride in the prevention of cisplatin-induced emesis. A randomized, double-blind, crossover study

11 December 2022

60

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

Methylprednisolone and chlorpromazine in patients receiving cancer chemotherapy: a prospective non-randomized study

11 December 2022

62

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

The serotonin type 3 receptor antagonist BRL 43694 and nausea and vomiting induced by cisplatin

11 December 2022

64

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

ONDANSETRON WITH AND WITHOUT DEXAMETHASONE TO TREAT CHEMOTHERAPY-INDUCED EMESIS

11 December 2022

65

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

Japanese Journal of Cancer and Chemotherapy

11 December 2022

67

9

1108

T Ise

1982

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

Methylprednisolone for chemotherapy-induced emesis: a double-blind randomized trial in children

11 December 2022

68

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

Risk and cost of gastrointestinal side effects associated with nonsteroidal anti-inflammatory drugs

11 December 2022

71

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

11 December 2022

72

63

1327

M Levitt

1979

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

The New England Journal of Medicine

11 December 2022

73

304

1237

M Haid

1981

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

Dexamethasone as an antiemetic during cancer chemotherapy

11 December 2022

74

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

11 December 2022

75

67

1013

MS Aapro

1983

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

The New England Journal of Medicine

11 December 2022

76

314

515

E Baharav

1986

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

Amelioration of cytotoxic-induced emesis with high-dose metoclopramide, dexamethasone and lorazepam

11 December 2022

79

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

Cataracts induced by intermittent Decadron used as an antiemetic

11 December 2022

80

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

The role of prostaglandins in the excessive nausea and vomiting after intravascular cis-platinum therapy

11 December 2022

82

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

Acute changes in blood-CSF barrier permselectivity to serum proteins after intrathecal methotrexate and CNS irradiation

11 December 2022

83

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

Cytotoxic-therapy-induced vomiting is mediated via enkephalin pathways

11 December 2022

84

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

Methylprednisolone for the control of CMF-induced emesis

11 December 2022

86

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

An effective five-drug antiemetic combination for prevention of chemotherapy-related nausea and vomiting. Experience in eighty-four patients

11 December 2022

87

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patients.

11 December 2022

88

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin

11 December 2022

89

1 reference

https://api.crossref.org/works/10.1007/978-3-642-84138-5_11

11 December 2022

Identifiers

0 references

1 reference